Viome has set out to identify the host and/or microbial molecular determinant of specific cancers by systematically evaluating the inflammatory conditions which have already been proven to increase the relative risk of cancer (e.g Inflammatory Bowel Disease as a precursor of colorectal cancer).
The precise characterization of the molecular signature associated with cancer pathogenesis might not only be used to predict or diagnose such cancer but also to support therapy with a companion diagnostic. Furthermore, specific molecular insights in the pathogenesis might also pave the way for the discovery and the development of new therapeutic approaches.
FDA Breakthrough Device
Viome has already achieved proof of concept for the detection of oral and throat cancers using saliva samples. Viome’s AI has discovered a molecular signature that includes several cancer hallmarks that represent molecular processes in human cancer cells, as well as a number of microbial pathways that are active in the oral cavity of cancer patients. This device was designated a breakthrough device by the FDA.
Our saliva liquid biopsy technology is anticipated to apply to other cancers as well, including other head and neck cancers, esophageal cancer, stomach cancer, pancreatic cancer, colorectal cancer, breast cancer, lung cancer, uterus cancer, and ovarian cancer, among others.